초록

Compositions, kits, and methods are provided directed to the treatment of prostate cancer using a maintenance dose of degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent.

대표청구항 ▼

1. A composition comprising degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent, wherein the composition is a dose and the dose of degarelix or pharmaceutically acceptable salt thereof ranges from 320 mg to 550 mg and the concentration of degarelix or pharmaceutically

1. A composition comprising degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent, wherein the composition is a dose and the dose of degarelix or pharmaceutically acceptable salt thereof ranges from 320 mg to 550 mg and the concentration of degarelix or pharmaceutically acceptable salt thereof ranges from 60 g to 80 mg of degarelix per mL of the solvent. 2. The composition according to claim 1, wherein the solvent is water. 3. The composition according to claim 1, wherein the excipient is mannitol. 4. The composition according to claim 1, wherein the concentration is 60 mg of degarelix per mL of the solvent. 5. The composition according to claim 1, wherein the dose of degarelix or pharmaceutically acceptable salt thereof ranges from 360 mg to 480 mg. 6. A kit comprising: at least one starting container comprising a lyophilisate of degarelix or pharmaceutically acceptable salt thereof and an excipient, wherein the lyophilisate of degarelix or pharmaceutically acceptable salt thereof is present in an amount ranging from 200 mg to 300 mg;at least one maintenance container comprising a lyophilisate of degarelix or pharmaceutically acceptable salt thereof and an excipient, wherein the lyophilisate of degarelix or pharmaceutically acceptable salt thereof is present in an amount ranging from 320 mg to 550 mg; andat least one container comprising a solvent. 7. The kit according to claim 6, further comprising an administration apparatus. 8. A kit comprising: at least one first container comprising a lyophilisate of degarelix or pharmaceutically acceptable salt thereof and an excipient, wherein the lyophilisate of degarelix or pharmaceutically acceptable salt thereof is present in an amount ranging from 320 mg to 550 mg; andat least one second container comprising a solvent. 9. The kit according to claim 8, further comprising an administration apparatus. 10. A method of preparing a starting concentration and a maintenance concentration for treating prostate cancer in a patient in need thereof comprising: combining at least one starting container comprising a lyophilisate of degarelix or pharmaceutically acceptable salt thereof with a dosage ranging from 200 mg to 300 mg of degarelix and an excipient with at least one container comprising a solvent, wherein the lyophilisate of degarelix or the pharmaceutically acceptable salt thereof and the excipient are dissolved in the solvent to achieve a concentration range from 20 mg to 80 mg of degarelix per mL of the solvent to form the starting concentration;combining, after an interval ranging from 14 to 56 days from the combination of the starting concentration, at least one maintenance container comprising a lyophilisate of degarelix or pharmaceutically acceptable salt thereof with a dosage ranging from 320 mg to 550 mg of degarelix and an excipient with at least one container comprising a solvent, wherein the lyophilisate of degarelix or the pharmaceutically acceptable salt thereof and the excipient are dissolved in the solvent to achieve a concentration range from 50 mg to 80 mg of degarelix per mL of the solvent to form the maintenance concentration; andrepeating, at least once, the combination of the at least one maintenance container with the at least one container comprising a solvent to form the maintenance concentration, after an interval ranging from 56 days to 112 days from the combination of the prior maintenance concentration. 11. A method of preparing a composition for treating prostate cancer comprising: combining at least one first container comprising a lyophilisate of degarelix or pharmaceutically acceptable salt thereof and an excipient with at least one second container comprising a solvent, wherein the lyophilisate of degarelix or the pharmaceutically acceptable salt thereof and the excipient are dissolved in the solvent to achieve a concentration range from 50 mg to 80 mg of degarelix per mL of the solvent. 12. A method of treating prostate cancer in a patient in need thereof comprising: administering to the patient a starting dose comprising degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent, wherein the starting dose ranges from 200 mg to 300 mg of degarelix or pharmaceutically acceptable salt thereof at a concentration ranging from 20 mg to 80 mg of degarelix per mL of the solvent;administering to the patient, at an interval ranging from 14 to 56 days after the administration of the starting dose, a first maintenance dose comprising degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent, wherein the maintenance dose ranges from 320 mg to 550 mg of degarelix or pharmaceutically acceptable salt thereof at a concentration ranging from 50 mg to 80 mg of degarelix per mL solvent; andrepeating, at least once, the administration of an additional maintenance dose to the patient, after an interval ranging from 56 days to 112 days from the administration of the prior maintenance dose. 13. The method according to claim 12, wherein the interval after the first maintenance dose for the administration of the at least one additional maintenance dose is 84 days. 14. The method according to claim 12, wherein the solvent is water. 15. The method according to claim 12, wherein the excipient is mannitol. 16. The method according to claim 12, wherein the interval after the administration of the starting dose is 28 days for the first maintenance dose. 17. The method according to claim 12, wherein the concentration of the starting dose is 40 mg of degarelix per mL of the solvent. 18. The method according to claim 12, wherein the concentration of the maintenance dose chosen from the first and the at least one additional maintenance dose ranges from 55 mg to 65 mg of degarelix per mL of the solvent. 19. The method according to claim 18, wherein the concentration of the maintenance dose chosen from the first and the at least one additional maintenance dose is 60 mg of degarelix per mL of the solvent. 20. The method according to claim 12, wherein the starting dose is 240 mg of degarelix or pharmaceutically acceptable salt thereof. 21. The method according to claim 12, wherein the maintenance dose chosen from the first and the at least one additional maintenance dose ranges from 360 mg to 480 mg of degarelix or pharmaceutically acceptable salt thereof. 22. The method according to claim 12, wherein 28 days after the administration of the starting dose, the patient exhibits a trough plasma concentration of at least 9 ng/mL. 23. The method according to claim 12, wherein after the administration of the maintenance dose chosen from the first and the at least one additional maintenance dose, the patient exhibits a trough plasma concentration of at least 9 ng/ml. 24. The method according to claim 12, wherein 3 days after the administration of the starting dose, the patient exhibits a serum testosterone level ranging from 0 ng/mL to 0.5 ng/mL. 25. The method according to claim 24, wherein after the administration of the maintenance dose chosen from the first and the at least one additional maintenance dose, the patient exhibits a serum testosterone level ranging from 0 ng/mL to 0.5 ng/mL. 26. A method of treating prostate cancer in a patient in need thereof comprising: administering to the patient a starting dose comprising degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent, wherein the starting dose is 240 mg of degarelix or pharmaceutically acceptable salt thereof at a concentration of 40 mg of degarelix per mL of the solvent;administering to the patient, 28 days after the administration of the starting dose, a first maintenance dose comprising degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent, wherein the maintenance dose is 480 mg of degarelix or pharmaceutically acceptable salt thereof at a concentration of 60 mg of degarelix per mL solvent; andrepeating, at least once, the administration of an additional maintenance dose to the patient 84 days after the administration of the prior maintenance dose. 27. The method according to claim 26, wherein 28 days after the administration of the starting dose, the patient exhibits a mean trough plasma concentration of at least 9 ng/mL. 28. The method according to claim 26, wherein after the administration of the maintenance dose chosen from the first and the at least one additional maintenance dose, the patient exhibits a mean trough plasma concentration of at least 9 ng/ml. 29. The method according to claim 26, wherein 3 days after the administration of the starting dose, the patient exhibits a serum testosterone level ranging from 0 ng/mL to 0.5 ng/mL. 30. The method according to claim 29, wherein after the administration of the maintenance dose chosen from the first and the at least one additional maintenance dose, the patient exhibits a serum testosterone level ranging from 0 ng/mL to 0.5 ng/mL. 31. A method of treating prostate cancer in a patient in need thereof comprising: administering to the patient a starting dose comprising degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent, wherein the starting dose is 240 mg of degarelix or pharmaceutically acceptable salt thereof at a concentration of 40 mg of degarelix per mL of the solvent;administering to the patient, 28 days after the administration of the starting dose, a first maintenance dose comprising degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent, wherein the maintenance dose is 360 mg of degarelix or pharmaceutically acceptable salt thereof at a concentration of 60 mg of degarelix per mL solvent; andrepeating, at least once, the administration of an additional maintenance dose to the patient 84 days after the administration of the prior maintenance dose. 32. The method according to claim 31, wherein 28 days after the administration of the starting dose, the patient exhibits a mean trough plasma concentration of at least 9 ng/mL. 33. The method according to claim 31, wherein after the administration of the maintenance dose chosen from the first and the at least one additional maintenance dose, the patient exhibits a mean trough plasma concentration of at least 9 ng/ml. 34. The method according to claim 31, wherein 3 days after the administration of the starting dose, the patient exhibits a serum testosterone level ranging from 0 ng/mL to 0.5 ng/mL. 35. The method according to claim 34, wherein after the administration of the maintenance dose chosen from the first and the at least one additional maintenance dose, the patient exhibits a serum testosterone level ranging from 0 ng/mL to 0.5 ng/mL.